Moreover, recent findings about somatic mutations that activate ErbB4 in metastatic melanoma have started to support a casual role of ErbB4 in carcinogenesis and to support the development of tools [28], such as ErbB4 antibodies, to target ErbB4 in cancer [29]. The gene discussed is ERBB4; the disease is metastatic melanoma.